What is the current recommended management for Alzheimer's disease at each stage of decline, including the optimal and contraindicated medications, assessment methods, and the role of disease-modifying biologic therapies?

Current Management of Alzheimer's Disease by Stage

For mild to moderate Alzheimer's disease, initiate treatment with cholinesterase inhibitors (donepezil, rivastigmine, or galantamine), while tacrine should be avoided due to hepatotoxicity; for moderate to severe disease, add memantine; and for early symptomatic AD with confirmed amyloid pathology, consider anti-amyloid monoclonal antibodies (lecanemab or donanemab) as disease-modifying therapy. 1, 2, 3, 4

Assessment and Diagnosis

Before initiating treatment, confirm the diagnosis through:

• Cognitive testing: Use standardized instruments (MMSE, ADAS-cog) to establish baseline cognitive function across multiple domains—memory, language, visuospatial skills, and executive function 5, 6
• Biomarker confirmation for anti-amyloid therapy: Amyloid PET or CSF testing is required before initiating lecanemab or donanemab; blood biomarkers (plasma p-tau 217, p-tau 181) are emerging as accessible alternatives with sensitivity ≥90% and specificity ≥85% 7, 8
• APOE ε4 genotyping: Essential before anti-amyloid therapy due to increased ARIA risk in carriers 4
• Structural MRI: Identify vascular contributions, rule out other pathology, and establish baseline for ARIA monitoring 6, 9

Stage-Based Pharmacologic Management

Mild to Moderate Alzheimer's Disease (MMSE 10-26)

First-line: Cholinesterase Inhibitors

Choose based on tolerability and dosing convenience—no head-to-head trials demonstrate superiority of one agent over another 1:

• Donepezil: Start 5 mg once daily, increase to 10 mg after 4-6 weeks. Preferred for once-daily dosing and lack of hepatotoxicity. Take with food to minimize GI side effects 1

• Rivastigmine: Start 1.5 mg twice daily, titrate by 3 mg/day every 4 weeks to maximum 12 mg/day. Higher doses more efficacious but monitor for weight loss 1

• Galantamine: Start 4 mg twice daily with meals, increase to 8 mg twice daily after 4 weeks, consider 12 mg twice daily based on tolerability. Contraindicated in hepatic or renal impairment 1

Avoid: Tacrine—causes liver enzyme elevation in 40% of patients, requires biweekly monitoring during titration and quarterly thereafter, plus four-times-daily dosing 1

Expected outcomes: 20-35% of patients show 7-point improvement on neuropsychologic tests (equivalent to delaying decline by one year). Set realistic expectations with patients and families—benefits are modest 1

Moderate to Severe Alzheimer's Disease (MMSE <10)

Add memantine to ongoing cholinesterase inhibitor therapy. Memantine modulates glutamatergic transmission and is recommended for severe dementia across international guidelines 10, 11

Combination therapy (memantine + donepezil) is specifically recommended for severe AD in US, Chinese, and Japanese guidelines 10

Early Symptomatic AD (MCI or Mild Dementia) with Confirmed Amyloid

Disease-modifying biologics represent a paradigm shift but require strict patient selection 3, 4:

Lecanemab or Donanemab—both demonstrate statistically significant and clinically meaningful slowing of cognitive and functional decline 4, 12

Mandatory requirements before initiation:

• Biomarker-confirmed amyloid pathology (PET, CSF, or validated blood biomarker) 7, 4
• APOE ε4 genotyping (homozygotes have higher ARIA risk) 4
• Baseline MRI to exclude microhemorrhages, superficial siderosis, or significant white matter disease 4

Critical safety monitoring:

• MRI surveillance for amyloid-related imaging abnormalities (ARIA-E [edema] and ARIA-H [hemorrhage]) at regular intervals during treatment 4, 12
• ARIA occurs in 12-37% of patients, higher in APOE ε4 carriers 4
• Most ARIA is asymptomatic but can cause headache, confusion, visual changes, or seizures 4

Key limitation: These therapies are indicated only for early symptomatic disease—not for moderate-severe dementia where neurodegeneration is too advanced 7, 3

Monitoring Treatment Response

Assess response at 6-12 months using 1:

• Physician global assessment
• Caregiver report of functional and behavioral changes
• Repeat cognitive testing (though brief mental status tests are relatively insensitive)
• Activities of daily living scales

Discontinue cholinesterase inhibitors if:

• Intolerable side effects persist despite dose adjustment
• Poor adherence
• Deterioration continues at pre-treatment rate after 6-12 months 1

Important: Patients who fail one cholinesterase inhibitor may respond to another—consider switching agents before abandoning this class 1

Agents to Avoid or Use with Caution

• Tacrine: Second-line only due to hepatotoxicity and QID dosing 1
• NSAIDs and estrogen: Insufficient evidence to recommend despite epidemiologic suggestions of benefit 1
• Vitamin E: One study showed 2,000 IU daily may slow functional decline, with expert consensus supporting its use, though evidence is limited 1
• Aducanumab: FDA-approved but controversial with limited efficacy evidence; not widely adopted in clinical practice 2

Role of Biologics: Current State

Anti-amyloid monoclonal antibodies (lecanemab, donanemab) represent the first disease-modifying treatments for AD, but their role is narrowly defined 3, 4, 12:

Appropriate use:

• Early symptomatic AD (MCI or mild dementia) only
• Confirmed amyloid pathology by biomarker
• Patients who can undergo regular MRI monitoring
• Adequate caregiver support for infusion visits and safety monitoring

Not appropriate for:

• Asymptomatic individuals (no approved indication for preclinical AD) 6, 8
• Moderate-severe dementia (too late for meaningful benefit)
• Patients with contraindications to MRI or multiple microhemorrhages
• Those unable to comply with intensive monitoring requirements

Real-world challenges: Implementation requires biomarker confirmation infrastructure, infusion capacity, MRI monitoring capability, and specialist expertise—creating significant access barriers 7, 3

Behavioral and Psychological Symptoms

Avoid antipsychotics as first-line—they increase risk of falls, stroke, and death 2

Prioritize: High-quality person-centered care and psychosocial interventions (cognitive stimulation, structured activities, caregiver training, environmental modifications) as first-line for agitation and behavioral symptoms 2, 13

Use antipsychotics only as carefully monitored, short-term, last resort in specific cases of severe agitation posing safety risk 2

Non-Pharmacologic Interventions

These are core therapies, not adjuncts 13, 11:

• Cognitive stimulation and training
• Physical exercise (aerobic and resistance)
• Mediterranean diet
• Caregiver education and support programs
• Environmental modifications for safety and orientation
• Management of cardiovascular risk factors, sleep disorders, and depression

Common Pitfalls to Avoid

1. Starting treatment without setting realistic expectations—communicate that cholinesterase inhibitors provide modest benefit (5-15% over placebo) 1

2. Using brief cognitive tests alone to assess drug response—they are insensitive; rely on caregiver reports and functional assessments 1

3. Abandoning cholinesterase inhibitors after one agent fails—try a different agent before concluding the class is ineffective 1

4. Initiating anti-amyloid therapy without proper biomarker confirmation and monitoring infrastructure—this creates serious safety risks 7, 4

5. Prescribing tacrine as first-line—hepatotoxicity and dosing burden make it second-line only 1

6. Using antipsychotics routinely for behavioral symptoms—reserve for severe cases after non-pharmacologic approaches fail 2

7. Overlooking caregiver burden and support needs—caregiver well-being directly impacts patient outcomes across all disease stages 1, 13